PERTH, Australia – Adelaide-based Bionomics Ltd.'s lead candidate, BNC-210, failed to meet the primary endpoint of decreasing symptoms in patients with post-traumatic stress disorder (PTSD) in its phase II trial, and the company is stopping development in PTSD. Shares of Bionomics (ASX:BNO) closed Tuesday at A17 cents (US12 cents), down A33 cents, or 66 percent, on the news.
PERTH, Australia – The Australian government's Medical Technology, Biotechnology and Pharmaceutical Industry Growth Center (MTPConnect) launched a new node in Western Australia to support the state's burgeoning life sciences sector, and it is continuing to build up skill sets in the country to prepare for future needs.
PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. is on its way to filing a BLA for its allogeneic mesenchymal precursor cell therapy, after it showed strong survival rates in children with acute steroid-refractory graft-vs.-host disease (aGVHD) at six months.
PERTH, Australia – Biotron Ltd. is crunching the data from a recently concluded phase II trial in HIV-1 that tested its lead compound BIT-225 in combination with antiretroviral (ARV) drugs, and the Melbourne-based company said it believes its approach to tackling viruses like HIV could wipe out the virus completely, Biotron CEO Michelle Miller told BioWorld Asia.
PERTH, Australia – The Australian government's Medical Technology, Biotechnology and Pharmaceutical Industry Growth Center (MTPConnect) launched a new node in Western Australia to support the state's burgeoning life sciences sector, and it is continuing to build up skill sets in the country to prepare for future needs.
PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. is on its way to filing a BLA for its allogeneic mesenchymal precursor cell therapy, after it showed strong survival rates in children with acute steroid-refractory graft-vs.-host disease (aGVHD) at six months.
PERTH, Australia – Biotron Ltd. is crunching the data from a recently concluded phase II trial in HIV-1 that tested its lead compound BIT-225 in combination with antiretroviral (ARV) drugs, and the Melbourne-based company said it believes its approach to tackling viruses like HIV could wipe out the virus completely, Biotron CEO Michelle Miller told BioWorld.
